AN2 Therapeutics, Inc. ( (ANTX) ) has released its Q3 earnings. Here is a breakdown of the information AN2 Therapeutics, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AN2 Therapeutics, Inc., a biopharmaceutical company based in Menlo Park, California, focuses on developing novel small molecule therapeutics using its boron chemistry platform, targeting diseases such as Chagas disease and non-tuberculous mycobacterial lung disease. In its latest earnings report for the quarter ended September 30, 2025, AN2 Therapeutics highlighted a net loss of $9.4 million, a decrease from the $12.7 million loss in the same period last year, reflecting reduced operating expenses. The company’s cash and cash equivalents decreased to $18 million from $21.4 million at the end of 2024, while short-term investments also saw a decline. Despite the financial losses, AN2 Therapeutics continues to focus on its research and development efforts, with significant investments in its pipeline. Looking ahead, AN2 Therapeutics remains committed to advancing its product candidates through clinical trials, with management expressing confidence in their ability to secure additional funding to support ongoing operations and future growth.